DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
RiskLD is a physician-led startup out of Cleveland focused on improving maternity outcomes.
Andrew Malloy spent a career on Wall Street and also happens to be part of a 3rd generation family office created because of his...
